Resonance Health funds three growth bets after oversubscribed raise

Oversubscribed placement strengthens Resonance’s balance sheet

Resonance Health Ltd (ASX:RHT) has raised $6.0 million from institutional, professional and sophisticated investors, with the placement described as oversubscribed and supported by both existing and new institutions. The 83.3 million new shares will be issued at 7.2 cents each, a 6.4% discount to the five-day VWAP and a 12.2% discount to the 22 October closing price.

The capital raise is sizeable relative to Resonance’s existing equity base: the new shares represent 14.9% of enlarged issued capital, lifting shares on issue from 477.1 million to 560.4 million. Settlement is expected on 6 November, with the new stock scheduled to begin trading on 9 November. No shareholder approval is required because the issue falls within existing placement capacity.

Three programmes receive two years of funding

After approximately $5.6 million in net proceeds, pro forma cash rises to $10.4 million and net cash to $7.9 million, compared with $4.8 million and $2.3 million respectively at 30 June 2026. Resonance says the balance sheet will fund its three growth programmes in full over 24 months, while retaining a $1.4 million working capital buffer for the timing of contract milestones and potential bolt-on acquisitions.

The largest allocation is not a single bet. Resonance has earmarked $1.2 million for additional MRI endpoints covering muscle fat and mass and automated visceral and subcutaneous fat analysis; $1.5 million for the first four of six planned east coast TrialsWest sites; and another $1.5 million for model refinement, validation, FDA pre-submission work and investigational deployment of the liver fibrosis device. The remaining funds cover working capital and offer costs.

The MRI expansion builds on the company’s existing imaging business and its recently announced IAG MRI alliance, which made its quantitative MRI endpoints orderable through Image Analysis Group’s global clinical-trial network. That alliance has no minimum revenue or volume commitments, so the new capital is funding capability and market access rather than contracted revenue.

Preliminary fibrosis results provide a signal, not clearance

The placement presentation also disclosed interim results from the extended proof-of-concept DEVIMLA study. Based on 50 of 68 enrolled subjects at a single China site, the investigational device produced an area under the curve of 0.820 for significant fibrosis of at least F2, with 75.0% sensitivity and 80.0% specificity. For advanced fibrosis of at least F3, the reported AUC was 0.788, with 57.9% sensitivity and 93.5% specificity.

Those figures are preliminary, have not been independently verified and come from a small cohort spanning a broad range of clinical conditions, including liver cancer. The company explicitly says the device is not cleared for clinical use in any jurisdiction. The next steps include completing analysis of all 68 subjects, independent pathology review, model development, FDA pre-submission discussions and a future validation study.

That makes the fibrosis programme the clearest source of upside and uncertainty in the capital plan. Resonance’s proposed route begins with investigational use in pharmaceutical trials, where sponsors would pay for scans that may help build the dataset required for regulatory submission. Any diagnostic market opportunity remains dependent on clinical validation, FDA feedback, clearance and eventual payer decisions.

Profitable base gives the expansion room to run

The raise follows FY26 profit and cash flow rather than a loss-making funding rescue. FY26 revenue increased 42% to $15.8 million, statutory NPAT reached $1.5 million, normalised EBITDA was $2.6 million and operating cash flow was positive in every quarter, producing a $2.9 million annual inflow.

Resonance has guided to FY27 revenue of $17 million to $22 million and EBITDA of $2.6 million to $3.6 million. That guidance excludes revenue from the fibrosis device, acquisitions, new TrialsWest sites and geographic expansion, leaving the three funded programmes as potential additions rather than assumptions embedded in the forecast.

The immediate test is execution across several fronts at once: converting MRI development into customer orders, opening the first east coast sites, progressing the fibrosis device through regulatory work and maintaining cash generation while the business expands. The NAB facility, which has $2.5 million drawn, matures on 31 March 2027 and is due for renewal discussions early next year.